Latest News and Press Releases

PharmAla signs a binding letter of intent to spin out its APA-01 novel asset into a joint venture with Aluvaris and Diteba, with deal to close in June.

Founded in April 1986 to advance psychedelic research and knowledge, MAPS has raised more than $150 million, supported 45 studies, and shaped the global policy and cultural landscape of...

PharmAla files Q2 quarterly financials with increased customer deposits.

PharmAla is positioned to supply the US market with MDMA, and is advancing its next-generation patented safer MDMA product for human dosing this year.

PharmAla provides an update on Cortexa, its Australian joint venture with Vitura Health.

Pharmala announces a newly signed contract to supply a clinical trial, and the fulfillment of a previously announced trial.

PharmAla to receive clinical trial data from harvard-affiliated hospital in exchange for a drug donation

PharmAla to supply University of Amsterdam with LaNeo MDMA for a clinical trial, generating new stability data for blister packs in the process

PharmAla announces the resignation of Dr. Malik Slassi and the appointment of Mr Lennie Ryer to its board.

Anonymous survey with optional confidential interviews will document how practitioners facilitate MDMA-assisted couples therapyFindings to inform ethical guidelines, future clinical trial protocols,...